• Ametek (Berwyn, Pennsylvania) said it has acquired Reichert Technologies (Depew, New York), a manufacturer of analytical instruments and diagnostic devices for the eye care market. The company was acquired for $150 million from Beecken Petty O'Keefe & Company and has estimated annual sales of $55 million. Reichert develops high-technology instruments used by ophthalmologists, optometrists, and opticians for vision correction and the screening and diagnosis of eye diseases such as glaucoma and macular degeneration. Reichert joins Ametek as part of its electronic instruments group (EIG). Ametek EIG sells its instruments to the process and analytical, aerospace, power, and industrial markets worldwide and had 2010 sales of $1.3 billion.

• Atrium Medical (Hudson, New Hampshire) said that it has signed a definitive agreement to be acquired by the Getinge Group (Stockholm, Sweden) and its subsidiary, Maquet Cardiovascular (Wayne, New Jersey), a provider of cardiovascular technologies for $680 million. Atrium specializes in interventional cardiology and radiology, chest trauma care and thoracic drainage, vascular surgery, and general surgery. Atrium will operate as an independent, self-contained business unit of Maquet Cardiovascular and will continue to be led by current Atrium President, Trevor Carlton.

• Bruker (Billerica, Massachusetts) reported the closing of its acquisition of Center for Tribology (CETR; Campbell, California) for $13 million in cash as an initial purchase price, with potential additional earn-out payments of up to $4 million in cash, depending on growth and profitability of the CETR-business within Bruker in 2012 and 2013. CETR, a privately held tribology and mechanical testing company with 30 employees, has now become a part of the Bruker Nano Surfaces division, joining the current AFM (atomic force microscope) and SOM (stylus and optical metrology) businesses. Norm Gitis, the founder and CEO of CETR, has joined Bruker as VP and General Manager of the new Bruker Tribology & Mechanical Testing (TMT) business.

• Conceptus (Mountain View, California), developer of the Essure procedure, a non-surgical permanent birth control method, said that it has acquired from its Dutch distributor certain assets and all distribution rights of the Essure device for about $3.6 million. The purchase was made by Conceptus' newly-formed subsidiary in the Netherlands, Conceptus BV. Conceptus BV will operate as a wholly owned subsidiary of Conceptus and its operating results will be consolidated within the company's operating results for financial reporting purposes beginning in 4Q11. Conceptus BV will assume certain employees who will focus solely on the sales and customer support of the Essure device. The acquisition will enable the company to recognize end-user sales pricing instead of distributor pricing, which is expected to generate incremental revenues and be accretive in 2012. Based on unit sales, the Netherlands is Conceptus' third largest European country market.

• C.R. Bard (Murray Hill, New Jersey) said it has an agreement in place to acquire Clearstream Technologies (Wexford, Ireland), a maker of catheters used in angioplasty procedures, in a deal worth about £43.8 million ($68.5 million). Bard will pay 85 pence per share ($1 .33) for all outstanding shares of Clearstream's stock, an 85% premium on its closing price of 45.89 pence per share on the London Stock Exchange. Bard, which manufacturers vascular, urology, oncology and surgical speciality products, has made the offer through Bard Bidco, its Irish unit. ClearStream's products are used by cardiologists, radiologists, and vascular surgeons in angioplasty procedures.

• Ethicon Endo-Surgery (Cincinnati) says it has an agreement to acquire privately-held SterilMed (Maple Grove, Minnesota), a developer in the reprocessing and remanufacturing of medical devices in the U.S. Financial terms of the agreement are not being disclosed. SterilMed offers products and services including medical device reprocessing, equipment repair, and pre-owned equipment sales that help healthcare providers lower their medical device and equipment costs, while reducing the amount of environmental waste they generate. EES says the acquisition broadens its portfolio and enables expansion in a rapidly growing market segment, while also bringing added scale, scope and experience to an already successful SterilMed team.

• NuVasive (San Diego, California), a company developing minimally disruptive surgical products and procedures for the spine, has agreed to acquire Impulse Monitoring (Columbia, Maryland), a intra-operative monitoring (IOM) provider in an $80 million deal comprised of $40 million in cash and $40 million in stock. Alex Lukianov, chairman/CEO of NuVasive, said the acquisition will further differentiate NuVasive's surgical solutions and add value to hospitals, surgeons, and patients by integrating products and services.

• OPKO Health (Miami) said that it has completed the sale of its ophthalmic instrumentation business to Optos (Marlborough, Massachusetts), a medical technology company that makes devices to image the retina of the eye. In connection with the sale, Optos paid OPKO $17.5 million in cash and agreed to pay future royalties. Optos acquired OPKO's worldwide activities for the development of ophthalmic diagnostic imaging systems and will combine OPKO's OCT SLO technology with Optos' widefield technology to provide a powerful tool to diagnose and manage diseases of the eye.